FYI - Phase 3 trial starting in Aug.2020 ... - Cure Parkinson's

Cure Parkinson's

25,860 members27,165 posts

FYI - Phase 3 trial starting in Aug.2020 for Light Therapy (Photo Bio Modulation)

John_morris71 profile image
8 Replies

May be you could enroll.

FDA grants breakthrough designation to a light device for the treatment of Parkinson’s

medcitynews.com/2020/05/fda...

Another site with more info

surfershealth.com.au/news/2...

............................................................................................................................................................

Company website ( Contact them about trial info etc. )

photopharmics.com/

.............................................................................................................................................................

The Food and Drug Administration recently awarded a breakthrough device designation for a phototherapy device intended to help patients with Parkinson’s Disease.

The non-invasive device is made by American Fork, Utah-based PhotoPharmics and is meant to be used at home, explained Kent Savage, CEO of PhotoPharmics, in an email response. The company’s website and press release claims that this is the first specialized light therapy device to receive such a priority designation for the FDA reserved for novel devices trying to fulfill an unmet patient need.

Our specialized phototherapy device is a prescription device intended as an adjunct therapy for the treatment of Parkinson’s disease and is intended to be used concurrently with standard dopaminergic therapy and is designed primarily for home use,” Savage said. “It is a table-top, therapeutic light source similar to a tablet, which generates soft blend of specific wavelengths of light that gently bathe the user’s face while they enjoy other activities such as watching TV, eating, reading or spending time online. Most enjoy the light each evening for an hour.

While the mechanism of action is unknown, a phase 2 trial conducted by the company showed that adding light therapy improved the motor and non-motor functions as well as the overall quality of life in patients suffering from Parkinson’s. Savage believes this is likely because specialized phototherapy helps to restore circadian function. Circadian rhythms regulate physical, mental and behavioral functions.

According to Parkinson’sDisesae.Net, research published in the February 2017 JAMA Neurology Journal, showed that “light therapy significantly reduced daytime sleepiness, improved sleep quality, decreased overnight awakenings, improved daytime alertness and activity level, and improved motor symptoms in people with Parkinson’s.”

However, this was mostly based on near-infrared light but Savage explained that near infrared light has been used in animal models and requires surgery.

PhotoPharmics has raised $11 million in a seed and Series A round from angel investors and others including Kickstart Seed Fund and Upstart Ventures. Savage is hoping to raise another $10 million in a Series B round currently underway.

There are other companies that are developing light therapy for depressive disorders or to treat certain behavioral symptoms associated with Alzheimer’s Disease.

“The most common light therapy solution on the market is ocular bright light therapy used in neuropsychiatric disorders. Unfortunately, the wavelengths and intensities of light from bright light therapy are inappropriate for PD patients,” Savage said.

Written by
John_morris71 profile image
John_morris71
To view profiles and participate in discussions please or .
Read more about...
8 Replies
park_bear profile image
park_bear

"phase 2 trial in Parkinson’s ... changes found on the MDS-UPDRS Parts 1+2 (experiences of daily living) (-4.0 points, p=0.037) "

Interesting.

photopharmics.com/largest-p...

John_morris71 profile image
John_morris71 in reply to park_bear

Since it is noninvasive and there are no drugs involved, there is an added incentive to enroll (in my opinion). I am hoping quite a few on this board would go ahead and see if they can meet enrollment criteria.

sharoncrayn profile image
sharoncrayn in reply to park_bear

" Although the study missed statistical significance in its primary endpoint..."

Doubtful Phase III will prove different.

Sharon

jeffreyn profile image
jeffreyn

Re: "Another site with more info"

The Surfers Health link does indeed provide more information, except that it is information about a completely different product, with a completely different mode of operation.

John_morris71 profile image
John_morris71 in reply to jeffreyn

Glad to know that you can read, decipher and have the time to reply.

jeffreyn profile image
jeffreyn in reply to John_morris71

You're welcome. Here is a recent, related article, which may be of interest to you, and to others.

surfershealth.com.au/news/2...

JayPwP profile image
JayPwP

Hope this becomes available soon

JayPwP profile image
JayPwP

Looks like a similar concept to "Another site with more info"

Reduces and Restrains Atherosclerosis, Memory Disorders, Dementia, Alzheimers, Parkinson's Disease.

rudralasers.com/

You may also like...

Light Therapy Trial: Update starting to recruit in December 2022

called a phase 3 trial). On top of FDA Breakthrough Device designation, we're pleased to let you...

Light Therapy Clinical Trial

clinicaltrials.gov DB RCT for Specialized Phototherapy in Parkinson's Disease. (LIGHT-PD) Here is...

First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's

Administration (FDA) gave the company the green light to start recruiting up to 450 patients with...

Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts

Red light therapy trial results

Australia, the new infrared light therapy helmet on patients living with Parkinson's helped improve...